Art. -Nr.: HY-12957

NITD008

(Synonyms: 7-Deaza-2'-C-acetylene-adenosine)

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

NITD008 is a potent and selective flaviviruse inhibitor which can inhibit Dengue Virus Type 2 (DENV-2) with an EC₅₀ of 0.64 μM. NITD008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.00%
CAS. Nr.: 1044589-82-3
Formel: C₁₃H₁₄N₄O₄
Molecular Weight:290.27

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

NITD008 Chemical Structure

CAS. Nr.: 1044589-82-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

EC50: 0.64 μM (DENV-2)^[1]

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	>100 μM Compound: 1	Cytotoxicity against human A549 cells assessed as intracellular ATP level by Celltiter-Glo luminescent assay Cytotoxicity against human A549 cells assessed as intracellular ATP level by Celltiter-Glo luminescent assay	[PMID: 20457821]
A549	CC₅₀	>100 μM Compound: NITD-008	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay	[PMID: 37159959]
A549	CC₅₀	>50 μM Compound: NITD008	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35306290]
A549	EC₅₀	0.46 μM Compound: NITD008	Antiviral activity against Dengue virus 3 MY22366 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 3 MY22366 infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	0.7 μM Compound: 1	Antiviral activity against at 0.3 MOI Dengue virus 2 infected in human A549 cells assessed as level of E protein after 48 hrs by ELISA Antiviral activity against at 0.3 MOI Dengue virus 2 infected in human A549 cells assessed as level of E protein after 48 hrs by ELISA	[PMID: 20457821]
A549	EC₅₀	0.7 μM Compound: NITD008	Antiviral activity against Dengue virus 4 MY22713 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 4 MY22713 infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	1.12 μM Compound: NITD008	Antiviral activity against Dengue virus 2 MY10340 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 2 MY10340 infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	1.64 μM Compound: NITD008	Antiviral activity against Dengue virus 2 NGC infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 2 NGC infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	2.61 μM Compound: NITD008	Antiviral activity against Dengue virus 1 MY10245 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 1 MY10245 infected in human A549 cells by CFI assay	[PMID: 20516277]
BHK-21	CC₅₀	>100 μM Compound: NITD-008	Cytotoxicity against hamster BHK-21 cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay Cytotoxicity against hamster BHK-21 cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay	[PMID: 37159959]
BHK-21	EC₅₀	0.7 μM Compound: 1	Antiviral activity against at 0.3 MOI of Dengue virus 2 infected in hamster BHK21 cells assessed as reduction in viral titer after 48 hrs postinfection Antiviral activity against at 0.3 MOI of Dengue virus 2 infected in hamster BHK21 cells assessed as reduction in viral titer after 48 hrs postinfection	[PMID: 20457821]
HEK293	EC₅₀	9.2 μM Compound: 1	Antiviral activity against Dengue virus 2 infected in human HEK293 cells assessed as level of viral titer after 48 hrs by luciferase reporter gene assay in presence of siRNA targeting adenosine kinase Antiviral activity against Dengue virus 2 infected in human HEK293 cells assessed as level of viral titer after 48 hrs by luciferase reporter gene assay in presence of siRNA targeting adenosine kinase	[PMID: 20457821]
Huh-7	CC₅₀	>100 μM Compound: NITD-008	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay	[PMID: 37159959]
Huh-7	CC₅₀	100 μM Compound: NITD-008	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter Glo Luminescent assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter Glo Luminescent assay	[PMID: 32435384]
Huh-7	CC₅₀	100 μM Compound: NITD-008	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescent assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescent assay	[PMID: 33208235]
Huh-7	CC₅₀	100 μM Compound: NITD008	Cytotoxicity against human Huh-7 cells treated for 48 hrs measured by celltitre-glo luminescent assay Cytotoxicity against human Huh-7 cells treated for 48 hrs measured by celltitre-glo luminescent assay	[PMID: 36965228]
Huh-7	EC₅₀	0.2 μM Compound: NITD-008	Antiviral activity against Zika virus H/PF/2013 infected in human HuH7 cells assessed as reduction in virus replication incubated for 24 hrs by plaque reduction assay Antiviral activity against Zika virus H/PF/2013 infected in human HuH7 cells assessed as reduction in virus replication incubated for 24 hrs by plaque reduction assay	[PMID: 32435384]
Huh-7	EC₅₀	1 μM Compound: NITD-008	Antiviral activity against Dengue virus 2 EDEN 3295 infected in human HuH7 cells assessed as reduction in virus replication incubated for 48 hrs by plaque reduction assay Antiviral activity against Dengue virus 2 EDEN 3295 infected in human HuH7 cells assessed as reduction in virus replication incubated for 48 hrs by plaque reduction assay	[PMID: 32435384]
PBMC	CC₅₀	>100 μM Compound: NITD-008	Cytotoxicity against human PBMC cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability measured after 48 hrs by Cell-titer glo luminescent assay	[PMID: 37159959]
PBMC	EC₅₀	0.58 μM Compound: NITD008	Antiviral activity against Dengue virus 2 NGC infected in human PBMC cells by plaque assay Antiviral activity against Dengue virus 2 NGC infected in human PBMC cells by plaque assay	[PMID: 20516277]
RD	CC₅₀	>20 μM Compound: 3; NITD008	Cytotoxicity against human RD cells assessed as reduction in cell viability by Cell Titer-Glo luminescent cell viability assay Cytotoxicity against human RD cells assessed as reduction in cell viability by Cell Titer-Glo luminescent cell viability assay	[PMID: 34560428]
RD	CC₅₀	>20 μM Compound: 4; NITD008	Cytotoxicity against human RD cells infected with CA16 incubated for 3 days by CellTiter 96 luminescent cell viability assay Cytotoxicity against human RD cells infected with CA16 incubated for 3 days by CellTiter 96 luminescent cell viability assay	[PMID: 35598412]
RD	CC₅₀	>20 μM Compound: 4; NITD008	Cytotoxicity against human RD cells infected with CA6 incubated for 3 days by CellTiter 96 luminescent cell viability assay Cytotoxicity against human RD cells infected with CA6 incubated for 3 days by CellTiter 96 luminescent cell viability assay	[PMID: 35598412]
RD	CC₅₀	>20 μM Compound: 4; NITD008	Cytotoxicity against human RD cells infected with EV71 incubated for 3 days by CellTiter 96 luminescent cell viability assay Cytotoxicity against human RD cells infected with EV71 incubated for 3 days by CellTiter 96 luminescent cell viability assay	[PMID: 35598412]
Vero	CC₅₀	>100 μM Compound: NITD008	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability treated for 3 days measured on day 4 by cell titer-blue fluorescent assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability treated for 3 days measured on day 4 by cell titer-blue fluorescent assay	[PMID: 26774922]
Vero	CC₅₀	>50 μM Compound: 3; NITD008	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 31549836]
Vero	CC₅₀	119.97 μM Compound: NITD008	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 27776325]
Vero	CC₅₀	74 μM Compound: NITD008	Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by DAPI staining based assay Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by DAPI staining based assay	[PMID: 36596229]
Vero	EC₅₀	0.03 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 4 Martinique 017 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 4 Martinique 017 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.08 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 4 Dakar HD34460 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 4 Dakar HD34460 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.12 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 3 Bolivia 4025 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 3 Bolivia 4025 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.67 μM Compound: NITD008	Antiviral activity against EV71 infected in African green monkey Vero cells after 48 hrs by plaque assay Antiviral activity against EV71 infected in African green monkey Vero cells after 48 hrs by plaque assay	[PMID: 27776325]
Vero	EC₅₀	0.82 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 2 Martinique H/IMTSSA-MART/98-703 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 2 Martinique H/IMTSSA-MART/98-703 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.86 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 1 Indonesia JKT 1186 TVP 949 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 1 Indonesia JKT 1186 TVP 949 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method	[PMID: 31549836]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay	[PMID: 31549836]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method	[PMID: 31549836]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay	[PMID: 31549836]

In Vitro

NITD008 potently inhibits other, including Dengue virus (DENV), West Nile virus, yellow fever virus, and Poissan virus. NITD008 inhibits DENV-2 in a dose-responsive manner, with an EC₅₀ value of 0.64 μM; treatment with 9 μM compound reduces viral titer by >104-fold^[1]. NITD008 also inhibits a luciferase-reporting replicon of hepatitis C virus (HCV, genotype 1b), a member from the genus Hepacivirus, with an EC₅₀ value of 0.11 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NITD008 is orally bioavailable and has good pharmacokinetic properties. NITD008 exhibits the best pharmacokinetic parameters when formulated using 6 N of HCl (1.5 equimolar amount), 1 N of NaOH (pH adjusted to 3.5), and 100 mM citrate buffer (pH 3.5). Following i.v. injection, NITD008 has a high volume of distribution (3.71 L/kg) and a low systemic clearance (31.11 mL/min per kg), resulting in a long elimination half-life (t_1/2=4.99 h). After p.o. dosing, NITD008 is rapidly absorbed (time of peak plasma concentration=0.5 h), with a maximal plasma concentration of 3 μM and bioavailability of 48%. Treatment of the mice immediately after viral infection with 1 mg/kg of NITD008 does not reduce mortality, but treatment with 3 mg/kg partially protects and treatment with ≥10 mg/kg completely protects the infected mice from death. NITD008 can suppress peak viremia, decrease cytokine elevation, and prevent death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1044589-82-3
Appearance Solid
Molecular Weight 290.27
Formel C₁₃H₁₄N₄O₄
Color White to gray
SMILES

O[C@@]1(C#C)[C@H](N2C=CC3=C(N)N=CN=C32)O[C@H](CO)[C@H]1O
Synonyms

7-Deaza-2'-C-acetylene-adenosine
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All

Sort by:

Journal Impact Factor

Nat Commun

A skin organoid-based infection platform identifies an inhibitor specific for HFMD. [Abstract]

2025 Mar 13;16(1):2513. PMID: 40082449
EMBO Mol Med

In vitro and in vivo inhibition of the host TRPC4 channel attenuates Zika virus infection. [Abstract]

2024 Aug;16(8):1817-1839. PMID: 39009885
Cell Rep

The HAVCR1-centric host factor network drives Zika virus vertical transmission. [Abstract]

2025 Mar 28;44(4):115464. PMID: 40156834
Eur J Med Chem

Investigation of novel 5'-amino adenosine derivatives with potential anti-Zika virus activity. [Abstract]

2023 Dec 5:261:115852. PMID: 37801825
J Biol Eng

Universal and quantitative detection of double-stranded RNAs as a signature of pan-virus infections using a luciferase-based biosensor. [Abstract]

2025 Dec 16. PMID: 41402836
PLoS Pathog

NS5-targeting nucleoside analogs inhibit dengue virus and other flaviviruses. [Abstract]

2026 Feb 17;22(2):e1013970. PMID: 41701758
Virol Sin

Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]

2024 Aug 19:S1995-820X(24)00134-2. PMID: 39168248
Antiviral Res

Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. [Abstract]

2022 Jun;202:105325. PMID: 35460703
Viruses

Azelnidipine Exhibits In Vitro and In Vivo Antiviral Effects against Flavivirus Infections by Targeting the Viral RdRp. [Abstract]

2022 Jun 5;14(6):1228. PMID: 35746699
Viruses

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. [Abstract]

2022 May 25;14(6):1142. PMID: 35746614
J Med Virol

Japanese Encephalitis Virus Genotype 5 Infectious Clone and Reporter System for Antiviral Evaluation. [Abstract]

2025 Sep;97(9):e70608. PMID: 40956224
Virus Res

Ondansetron exhibits potent antiviral activity against enterovirus 71 infection in vitro and in vivo. [Abstract]

2026 Jun 25:370:199771. PMID: 42349797
Virology

A cell-based assay to discover inhibitors of Zika virus RNA-dependent RNA polymerase. [Abstract]

2024 Jan:589:109939. PMID: 37979208
bioRxiv

2025 August 15.
bioRxiv

2025 April 07.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (172.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4451 mL

17.2253 mL

34.4507 mL

5 mM

0.6890 mL

3.4451 mL

6.8901 mL

10 mM

0.3445 mL

1.7225 mL

3.4451 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

For measurement of compound cytotoxicity, Vero cells (10000 cells per well of a 96-well plate) are incubated with various concentrations of NITD008 (3, 6, 12, 25, 50 μM) for 48 h; cell viability is quantified using a MTT assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]

The in vivo efficacy of NITD008 is evaluated in a dengue viremia model and a lethal model in mice. Both models use AG129 mice (with knockout IFN-α/β and IFN-γ receptors). DENV-2 strains TSV01and D2S10, respectively, are used in the 2 models and are propagated in C6/36 mosquito cells grown in RPMI-1640 medium with 5% FBS (vol/vol) at 28°C. The evaluation in the lethal model is performed by injecting mice i.v. with 0.2 mL of RPMI-1640 medium containing 3×10⁷ pfu/mL DENV-2 strain D2S10; the infected mice are then subjected to different treatment regimens, as indicated in each experiment. NITD008 (1, 3, 10, 25, 50 mg/kg) in 0.2-0.25 mL of formulation solution is administered by p.o. gavage. The mice (6 or 8 mice per group) are monitored twice a day^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yin Z, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4451 mL	17.2253 mL	34.4507 mL	86.1267 mL
	5 mM	0.6890 mL	3.4451 mL	6.8901 mL	17.2253 mL
	10 mM	0.3445 mL	1.7225 mL	3.4451 mL	8.6127 mL
	15 mM	0.2297 mL	1.1484 mL	2.2967 mL	5.7418 mL
	20 mM	0.1723 mL	0.8613 mL	1.7225 mL	4.3063 mL
	25 mM	0.1378 mL	0.6890 mL	1.3780 mL	3.4451 mL
	30 mM	0.1148 mL	0.5742 mL	1.1484 mL	2.8709 mL
	40 mM	0.0861 mL	0.4306 mL	0.8613 mL	2.1532 mL
	50 mM	0.0689 mL	0.3445 mL	0.6890 mL	1.7225 mL
	60 mM	0.0574 mL	0.2871 mL	0.5742 mL	1.4354 mL
	80 mM	0.0431 mL	0.2153 mL	0.4306 mL	1.0766 mL
	100 mM	0.0345 mL	0.1723 mL	0.3445 mL	0.8613 mL

Keywords

NITD008

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NITD008

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) NITD008

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NITD008

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) NITD008

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NITD008 Related Classifications

HY-12957 Related Classifications